[go: up one dir, main page]

BRPI0814308A2 - Processo para o preparo de um complexo solúvel de composto resveratrol e ciclodextrina, complexo composto resveratrol e ciclodextrina, composição nutracêutica, composição farmacêutica, e uso do referido complexo - Google Patents

Processo para o preparo de um complexo solúvel de composto resveratrol e ciclodextrina, complexo composto resveratrol e ciclodextrina, composição nutracêutica, composição farmacêutica, e uso do referido complexo

Info

Publication number
BRPI0814308A2
BRPI0814308A2 BRPI0814308-0A2A BRPI0814308A BRPI0814308A2 BR PI0814308 A2 BRPI0814308 A2 BR PI0814308A2 BR PI0814308 A BRPI0814308 A BR PI0814308A BR PI0814308 A2 BRPI0814308 A2 BR PI0814308A2
Authority
BR
Brazil
Prior art keywords
complex
resveratrol
cyclodextrin
composition
nutrachetic
Prior art date
Application number
BRPI0814308-0A2A
Other languages
English (en)
Inventor
Andre Arigony Souto
Original Assignee
Ubea
Eurofarma Lab Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ubea, Eurofarma Lab Ltda filed Critical Ubea
Priority to BRPI0814308A priority Critical patent/BRPI0814308B8/pt
Publication of BRPI0814308A2 publication Critical patent/BRPI0814308A2/pt
Publication of BRPI0814308B1 publication Critical patent/BRPI0814308B1/pt
Publication of BRPI0814308B8 publication Critical patent/BRPI0814308B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/02Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof containing fruit or vegetable juices
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Nanotechnology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
BRPI0814308A 2007-07-23 2008-07-23 processo de preparo, complexo compreendendo resveratrol e ciclodextrina, composições e uso BRPI0814308B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0814308A BRPI0814308B8 (pt) 2007-07-23 2008-07-23 processo de preparo, complexo compreendendo resveratrol e ciclodextrina, composições e uso

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
BRPI0705319-3A BRPI0705319A2 (pt) 2007-07-23 2007-07-23 processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica
BRPI0705319-3 2007-07-23
BRPI0814308A BRPI0814308B8 (pt) 2007-07-23 2008-07-23 processo de preparo, complexo compreendendo resveratrol e ciclodextrina, composições e uso
PCT/BR2008/000216 WO2009012551A1 (en) 2007-07-23 2008-07-23 Resveratrol complex and process for the preperation

Publications (3)

Publication Number Publication Date
BRPI0814308A2 true BRPI0814308A2 (pt) 2015-02-03
BRPI0814308B1 BRPI0814308B1 (pt) 2020-10-27
BRPI0814308B8 BRPI0814308B8 (pt) 2021-05-25

Family

ID=40280935

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0705319-3A BRPI0705319A2 (pt) 2007-07-23 2007-07-23 processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica
BRPI0814308A BRPI0814308B8 (pt) 2007-07-23 2008-07-23 processo de preparo, complexo compreendendo resveratrol e ciclodextrina, composições e uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0705319-3A BRPI0705319A2 (pt) 2007-07-23 2007-07-23 processo para obtenção de um complexo solúvel de resveratrol e/ou seus derivados; complexo de resveratrol e/ou seus derivados; composição nutracêutica

Country Status (7)

Country Link
US (1) US8476248B2 (pt)
EP (1) EP2178525A4 (pt)
BR (2) BRPI0705319A2 (pt)
CA (1) CA2694343C (pt)
CO (1) CO6260022A2 (pt)
EC (1) ECSP109982A (pt)
WO (1) WO2009012551A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714161B2 (en) 2004-01-20 2010-05-11 Brigham Young University Sirtuin activating compounds and methods for making the same
BRPI0806044A2 (pt) * 2008-10-17 2010-09-14 Ubea método e kit para determinação de agentes moduladores de sirtuìnas, processo para modulação de sirtuìnas, compostos moduladores de sirtuìnas e composições compreendendo os mesmos
WO2010058242A1 (en) * 2008-11-24 2010-05-27 Giovanni Nicolao Berta New formulations with anti-neoplastic activity
BRPI0900400B1 (pt) * 2009-02-10 2017-12-19 União Brasileira De Educação E Assistência Composition understanding vegetable oil and resveratrol and process for producing them
WO2010102245A1 (en) * 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
EP2445488B1 (en) * 2009-06-22 2020-03-18 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
RU2464042C1 (ru) * 2011-03-31 2012-10-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
CN103120310A (zh) * 2011-11-20 2013-05-29 重庆还少堂生物技术有限责任公司 白藜芦醇水溶性干粉的制配方法
CN103356476B (zh) * 2012-03-31 2016-02-17 昆药集团股份有限公司 溶解黄酮类化合物、碳苷类化合物或茋类化合物的方法及注射液或注射用粉针剂的制备方法
ITRM20120275A1 (it) * 2012-06-13 2013-12-14 Noos S R L Associazione di resveratrolo e carbossimetilglucano.
KR101480600B1 (ko) * 2013-01-22 2015-01-08 경북대학교 산학협력단 레스베라트롤 유도체의 피부미백 용도
RU2594281C2 (ru) * 2013-04-03 2016-08-10 Чайна Медикал Юнивёсити Стильбеноидные соединения в качестве ингибиторов плоскоклеточной карциномы и гепатомы и их применения
WO2015027068A1 (en) * 2013-08-21 2015-02-26 Concordia University Dendrimer-resveratrol complex
JP6435158B2 (ja) * 2014-10-17 2018-12-05 森永製菓株式会社 精製スチルベン化合物の製造方法
WO2016168772A1 (en) * 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
SMT202100499T1 (it) * 2017-01-09 2021-09-14 Scipharm S A R L Nuovo metodo perp preparare un complesso di forskolina
CN108774290B (zh) * 2018-07-10 2020-09-04 宁夏蓝博思化学技术有限公司 白藜芦醇-羧烷基型环糊精衍生物及其制备方法
WO2020023807A1 (en) * 2018-07-26 2020-01-30 The Regents Of The University Of California Treatment of vascular occlusion by activation of notch signaling
EP3603415B1 (fr) * 2018-07-30 2020-12-30 Universite D'Avignon et Des Pays Du Vaucluse Procede d'extraction de composes phenoliques
US10882012B2 (en) * 2018-08-03 2021-01-05 Wakamono Corporation Process for producing a nano resveratrol microemulsion system
TWI689304B (zh) * 2018-12-04 2020-04-01 高雄醫學大學 抗霧霾組合物
CN111001013B (zh) * 2019-12-12 2023-04-18 安徽工业大学 一种枇杷叶提取物纳米胶囊、制备方法及应用
CN111387393B (zh) * 2020-05-07 2022-09-20 北京维泰力特生物医药有限公司 一种含有小分子肽、白藜芦醇和花青素的饮料及其制备方法
CN114681354A (zh) * 2020-12-31 2022-07-01 苏州悦肤达医疗科技有限公司 一种微针贴片及其制备方法
JP2022167624A (ja) * 2021-04-23 2022-11-04 株式会社常磐植物化学研究所 ショウガポリフェノールの体内吸収改善方法、及び、ポリフェノール体内吸収改善用組成物
CN114656645B (zh) * 2022-03-23 2023-02-24 齐鲁工业大学 一种在水相中稳定存在的环糊精金属有机框架的制备方法
WO2025008074A1 (en) 2023-07-06 2025-01-09 Wacker Chemie Ag Process for preparing cyclodextrin resveratrol compositions with high solubility
CN118021996B (zh) * 2024-01-16 2024-07-30 华南理工大学 一种抗菌包合材料及其制备方法和应用
US20250241870A1 (en) * 2024-01-30 2025-07-31 Caliway Biopharmaceuticals Co., Ltd. Oxyresveratrol and derivatives thereof for use in lipolysis
CN119499226B (zh) * 2025-01-17 2025-05-23 北京市农林科学院 高稳定性及生物可及性白藜芦醇-果胶复合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884885B2 (en) * 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators

Also Published As

Publication number Publication date
CO6260022A2 (es) 2011-03-22
CA2694343C (en) 2016-03-29
CA2694343A1 (en) 2009-01-29
WO2009012551A4 (en) 2009-03-12
WO2009012551A1 (en) 2009-01-29
ECSP109982A (es) 2010-04-30
BRPI0814308B1 (pt) 2020-10-27
EP2178525A1 (en) 2010-04-28
BRPI0705319A2 (pt) 2009-07-21
EP2178525A4 (en) 2013-08-28
BRPI0814308B8 (pt) 2021-05-25
US8476248B2 (en) 2013-07-02
US20100204179A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
BRPI0814308A2 (pt) Processo para o preparo de um complexo solúvel de composto resveratrol e ciclodextrina, complexo composto resveratrol e ciclodextrina, composição nutracêutica, composição farmacêutica, e uso do referido complexo
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0816331A2 (pt) Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0920955A2 (pt) processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
BRPI0815360A2 (pt) Composto derivado de 4-pirimidinossulfamida, composição farmacêutica que o contem, uso e processo para pa preparação do composto
BRPI0814611A2 (pt) Composição, processo para preparar uma composição, e, uso de uma composição
BRPI0611956A2 (pt) composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto
BRPI1013403A2 (pt) prepregs, processo para a produção destes, uso dos mesmos, uso da composição de poliuretano, componentes de compósitos e processo para a produção de componentes de compósitos.
BRPI0813237A2 (pt) Composto, método para preparar o composto, composição, medicamento, e, uso do composto.
BRPI0915803A2 (pt) processo para aumentar a cristalinidade de pelo menos um material sólido, partícula, composição farmacêutica, e, inalador
BRPI0924427A2 (pt) composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
BRPI0721404A2 (pt) Moldagem, composição de moldagem, processo para produção de moldagens e uso da mesma
BRPI0814821A2 (pt) Composto, composição farmacêutica, e, processo para preparar um composto
BRPI0918487A2 (pt) processo para a preparação de uma composição de copolímero, composição, e, uso de uma composição de copolímero
BRPI0911554A2 (pt) Microemulsão, processo para a preparação de uma microemulsão, e, uso da microemulsão.
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
BR112012016201A2 (pt) ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto''
BRPI0822946A2 (pt) Derivado de carboxiamida, processo para preparação de derivado de carboxiamida, composição farmacêutica e uso do derivado de carboxiamida
BRPI0813438A2 (pt) Processo para preparar um composto, uso de um composto, e, composto.
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo
BRPI0815975A2 (pt) Preparação aquosa, recipiente farmacêutico, processo para preparar uma preparação aquosa, e, uso de uma preparação aquosa
BRPI0907987A2 (pt) uso de malonatos de benzilideno, processo para a preparação de compostos, preparação cosmética, e compostos
BRPI1016109A2 (pt) "composto, composição farmacêutica, e, processo para preparar um composto"
BRPI0822066A2 (pt) derivados diolatos daizênio, o respectivo processo de preparo e as composições farmacêuticas que os contêm

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UNIAO BRASILEIRA DE EDUCACAO E ASSISTENCIA - MANTE

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF